OrthoPediatrics Corp. (NASDAQ:KIDS) Director (Reynolds) Marie C. Infante sold 359 shares of OrthoPediatrics stock in a transaction dated Tuesday, September 7th. The stock was sold at an average price of $69.19, for a total transaction of $24,839.21. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
KIDS opened at $69.65 on Wednesday. The company has a market cap of $1.37 billion, a price-to-earnings ratio of -40.97 and a beta of 0.69. OrthoPediatrics Corp. has a 52-week low of $38.01 and a 52-week high of $72.50. The firm’s fifty day simple moving average is $64.46 and its two-hundred day simple moving average is $58.46.
OrthoPediatrics (NASDAQ:KIDS) last posted its quarterly earnings data on Wednesday, August 4th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.21) by $0.10. The business had revenue of $26.70 million for the quarter, compared to the consensus estimate of $24.14 million. OrthoPediatrics had a negative net margin of 36.61% and a negative return on equity of 7.64%. As a group, sell-side analysts expect that OrthoPediatrics Corp. will post -0.9 earnings per share for the current fiscal year.
KIDS has been the subject of several research reports. Needham & Company LLC boosted their price objective on shares of OrthoPediatrics from $70.00 to $77.00 and gave the company a “buy” rating in a research report on Monday, June 14th. Piper Sandler upped their price target on shares of OrthoPediatrics from $70.00 to $80.00 and gave the stock an “overweight” rating in a research report on Thursday, August 5th. JMP Securities upped their price target on shares of OrthoPediatrics from $70.00 to $77.00 and gave the stock an “outperform” rating in a research report on Friday, August 6th. Finally, Zacks Investment Research upgraded shares of OrthoPediatrics from a “hold” rating to a “buy” rating and set a $77.00 price objective for the company in a research note on Wednesday, August 11th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $73.14.
OrthoPediatrics Corp. is a medical device company, which engages in the design, development, and marketing of anatomically appropriate implants and devices for children with orthopedic conditions. Its products includes PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, RESPONSE Spine, Bandloc and Pediguard.
Featured Article: Conference Calls
Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.